

AbbVie Clinical Pharmacology Research Unit
 Information Sheet
 www.abbviephase1.com

Peacock

Check In Date: Wednesday, 01 June 2022 and Tuesday, 21 June 2022

Study drug and design:

AbbVie is testing an investigational drug, which is not approved by the Food and Drug Administration (FDA) or any health authority and is not currently available in the market. The objective of the study is to assess the safety, tolerability, and the pharmacokinetics (the amount of drug absorbed in your bloodstream and how your body handles the drug) of the investigational drug.

Minimum Subject Selection Criteria:

YOU may be eligible to take part in this clinical study if you meet the following conditions:

- ◆ Healthy men and women 18 to 65 years old.
- ◆ Females must be permanently surgically sterile or postmenopausal for 1 year.
- ◆ Average weight for height (BMI 18.0 to 32.0).
- ◆ Not taking any medications or herbal remedies or supplements.
- ◆ No history of clinically significant condition: any metabolic or endocrine disease, including diabetes and thyroid disease.
- ◆ No history of gastrointestinal surgical operations including removal of the gallbladder.
- ◆ No history of dysplasia or history of malignancy.
- ◆ No history of any drug sensitivity or allergy.
- ◆ No history of drug or alcohol abuse for 6 months.
- ◆ Non-user of tobacco for at least 6 months.
- ◆ No use of known inhibitors (e.g., ketoconazole) or inducers (e.g., carbamazepine) of CYP3A, or inhibitor (e.g., fluconazole) or inducers (e.g., rifampicin) of cytochrome P450 2C9 (CYP2C9) within 30 days prior to the first dose of the study drug.
- ◆ No live vaccine after 01 May 2022.
- ◆ No blood or blood product donation after 04 April 2022
- ◆ No other study participation after 01 May 2022 or 5 half-lives of the drug if known.

Screenings at ACPRU in Grayslake

Screening dates: *(To find out if you are suitable to take part in this clinical study)*

- ◆ May 20, 23, 24, 25, or 26 May 2022.
- ◆ **Additional screening dates may be available.**
- ◆ Screening appointments are between the hours of 0800 and 1100 and take approximately 3 hours.

Stipend:

- ◆ **Screening:** \$75.00. (No compensation if urine drug/alcohol/cotinine screen is positive or if BMI is out of range.)

AbbVie Clinical Pharmacology Research Unit
Information Sheet
www.abbviephase1.com

- ◆ **Study:** Compensation of up to \$7,000 may be provided if selected and you complete the study.

Study dates: *(Please note that these dates and times are subject to change)*

Must complete all periods and/or follow up visit(s).

CHECK IN: Wednesday, 01 June 2022 and Tuesday, 21 June 2022 at scheduled appointment time.

CHECK OUT: Thursday 09 June 2022 and Wednesday 29 June 2022 approximately at noon.

FOLLOW UP PHONE CALL(S): Friday, 22 July 2022.

(A follow up visit may be required for safety. If this occurs, you will be notified and compensated for your visit time and travel)

(Please note that these dates and times are subject to change)

Please call our recruiting office at 1-800-827-2778 to schedule an appointment.